223 related articles for article (PubMed ID: 37208599)
1. The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
Hu X; Luo H; Tan G; Li Y; Qin B
BMC Gastroenterol; 2023 May; 23(1):163. PubMed ID: 37208599
[TBL] [Abstract][Full Text] [Related]
2. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
[TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study.
Bahardoust M; Mokhtare M; Barati M; Bagheri-Hosseinabadi Z; Karimi Behnagh A; Keyvani H; Agah S
J Infect Chemother; 2020 Dec; 26(12):1265-1271. PubMed ID: 32762882
[TBL] [Abstract][Full Text] [Related]
6. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients.
Li J; Qu L; Sun X; Liu Y; Gong Q; Yu D; Zhang D; Jiang J; Chen J; Wei D; Han Y; Gao Y; Zhang Q; She W; Chen L; Zhang J; Zhang X
J Viral Hepat; 2021 Oct; 28(10):1381-1391. PubMed ID: 34228855
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone.
Lin S; Fu Y; Wu W; Chen T; Chen N; Xun Z; Liu C; Ou Q; Zeng Y; Huang H
Int J Med Sci; 2020; 17(10):1458-1463. PubMed ID: 32624702
[No Abstract] [Full Text] [Related]
8. [Effect of tenofovir disoproxil fumarate antiviral therapy on virus-specific CD8+T Cells function in patients with chronic hepatitis B].
Duan SP; Zhu LH; Hou LJ; Wang HW; Zhu XW; Hao J
Zhonghua Gan Zang Bing Za Zhi; 2021 May; 29(5):421-426. PubMed ID: 34107578
[No Abstract] [Full Text] [Related]
9. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study.
Lian J; Kuang W; Jia H; Lu Y; Zhang X; Ye C; Gu J; Lv Y; Yu J; Zhang Y; Lu X; Zhao Y; Yang D; Wang K; Zhao P; Yu Y; Bai L; Zhang J; Zhang X; Yang Y
J Med Virol; 2022 Nov; 94(11):5475-5483. PubMed ID: 35836102
[TBL] [Abstract][Full Text] [Related]
14. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol.
Zhu S; Wu L; Mei Y; Liu Z; Lin L; Yuan J; Li J; Li X; Peng L
BMJ Open; 2021 Oct; 11(10):e049104. PubMed ID: 34697111
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
Marcellin P; Ahn SH; Chuang WL; Hui AJ; Tabak F; Mehta R; Petersen J; Lee CM; Ma X; Caruntu FA; Tak WY; Elkhashab M; Lin L; Wu G; Martins EB; Charuworn P; Yee LJ; Lim SG; Foster GR; Fung S; Morano L; Samuel D; Agarwal K; Idilman R; Strasser SI; Buti M; Gaeta GB; Papatheodoridis G; Flisiak R; Chan HL
Aliment Pharmacol Ther; 2016 Nov; 44(9):957-966. PubMed ID: 27629859
[TBL] [Abstract][Full Text] [Related]
16. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Ahn SH; Marcellin P; Ma X; Caruntu FA; Tak WY; Elkhashab M; Chuang WL; Tabak F; Mehta R; Petersen J; Guyer W; Jump B; Chan A; Subramanian M; Crans G; Fung S; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HLY
Dig Dis Sci; 2018 Dec; 63(12):3487-3497. PubMed ID: 30136045
[TBL] [Abstract][Full Text] [Related]
18. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir
Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
